supernus pharmaceuticals

News

Supernus To Acquire Sage

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million.The terms of the deal also include one non-tradable contingent value right (CVR) payable upon achieving certain sales goals,

Zacks Investment Research on MSN · 3h

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

· 1d

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

GlobalData on MSN1d

Supernus makes depression drug play with $795m Sage buyout

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Fierce Pharma1d

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

pharmaphorum1d

After rebuffing Biogen, Sage pairs off with Supernus

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Zacks.com on MSN6h

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Explore more

Sage Therapeutics

Zurzuvae

TMCnet1d

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results